Classification is the first analytical step in any Thailand device registration strategy, and the first point at which foreign manufacturers go wrong. Thailand uses a 4-class risk-based system aligned with the ASEAN Medical Device Directive (AMDD). FDA risk categories and EU MDR classification rules do not map directly to Thai AMDD criteria. A device classified by analogy to its home-market class is frequently wrong, and a misclassified application is rejected at screening.
Under the Medical Device Act B.E. 2551 (2008) as amended by B.E. 2562 (2019), device class determines the registration pathway (listing, notification, or full license), the fee structure, the documentation package required, and whether ISO 13485 certification is mandatory. None of these downstream decisions can be made correctly until the class is confirmed against Thai AMDD criteria.
The Medical Devices Control Division (MDCD) of Thai FDA screens applications for classification accuracy before advancing them to review. An application submitted under the wrong class does not get rerouted to the correct pathway; it is rejected. The application fee is not refunded. The registration timeline restarts from the beginning under the correct class.
Classification is not a judgment call the foreign manufacturer makes at its own discretion. It is a determination made against defined AMDD criteria, applied to the device as it will be used in Thailand. When the intended use in Thailand differs from the intended use under the home-market registration, the Thai classification may also differ.
Thailand's classification rules follow the ASEAN Medical Device Directive (AMDD). The MDCD applies 4 primary criteria to determine the correct class for any device. Each criterion is applied to the device as used in its stated intended use, not to the device as a physical object in isolation.
Whether the device enters the body through a body orifice or through the body surface, and to what extent. Non-invasive devices are generally lower class; surgically invasive devices that penetrate through the skin or body wall are generally higher class. The degree of invasiveness and the anatomical location both contribute to the classification determination.
Transient contact (less than 60 minutes), short-term contact (60 minutes to 30 days), and long-term contact (more than 30 days) are defined contact duration categories under the AMDD. Extended contact duration increases the risk classification. An implantable device with permanent contact is treated differently from a device with transient skin contact, even within the same invasiveness category.
The clinical function the device is designed and labeled to perform. A device intended to diagnose, treat, monitor, or replace a physiological function is assessed against the risk associated with that function. A device intended to support a life-sustaining function is generally Class 4. Intended use is established by the manufacturer's own labeling and documentation; Thai FDA will classify based on what the manufacturer states, not what might be inferred from the device's physical design.
An active device relies on an external energy source other than gravity or energy directly generated by the human body. Active devices that administer or exchange energy with the patient are generally higher class than non-active equivalents. Active implantable devices are among the highest-risk categories under the AMDD. Software-based medical devices are classified based on their intended clinical function and the consequence of failure.
Each class has a defined registration pathway, a confirmed fee structure, and specific certification requirements. Fees cited below are drawn from Thai FDA's official English portal and are confirmed as of 2024 to 2026. All fees are denominated in Thai Baht (THB).
Total import fee: 3,100 THB. No expert review fee. ISO 13485 is not required; Class 1 devices must follow Thai GMP guidelines. Required documentation: device description and features, Letter of Authorization from the foreign manufacturer, and conditional sterilization or calibration reports where applicable. Class 1 covers non-invasive devices with minimal patient contact risk, such as bandages, examination gloves, and basic diagnostic instruments not reliant on energy.
Total import fee: 11,000 THB, comprising a 1,000 THB application fee and a 10,000 THB certificate fee. Thai FDA rarely calls for expert review at this class; where it does, a further 38,000 THB applies, bringing the total to 49,000 THB. ISO 13485 certification is mandatory. Full CSDT dossier required. Class 2 covers devices such as contact lenses, non-invasive diagnostic imaging devices, and non-implantable surgical instruments with limited invasiveness.
Total import fee: 11,000 THB, with the same breakdown as Class 2. Thai FDA calls for expert review sometimes at this class, which adds 38,000 THB for a total of 49,000 THB. ISO 13485 certification is mandatory. Full CSDT dossier required. The documentation burden is higher than Class 2, reflecting the elevated risk profile. Class 3 covers devices such as orthopedic implants, long-term implantable devices not in direct contact with the cardiovascular system, and active therapeutic devices.
Total import fee: 21,000 THB, comprising a 1,000 THB application fee and a 20,000 THB certificate fee. Thai FDA calls for expert review often at this class, which adds 53,000 THB for a total of 74,000 THB. ISO 13485 certification is mandatory. This is the most demanding pathway in terms of documentation, clinical evidence, and expert review. Class 4 covers devices such as cardiac valves, active implantable devices, and devices used in direct contact with the central cardiovascular system or central nervous system where failure has direct life-threatening consequence.
The AMDD uses letter-based class labels (A, B, C, D) across ASEAN member states. Thailand uses numerical equivalents (1, 2, 3, 4). The risk structures are equivalent. Manufacturers with existing ASEAN registrations will encounter both labeling conventions and should apply the following equivalence when preparing documentation for a Thai submission.
Low risk. Listing pathway in Thailand. Documents from other ASEAN markets referencing AMDD Class A classification correspond to Thai Class 1.
Low-to-moderate risk. Notification pathway in Thailand. AMDD Class B documentation corresponds to Thai Class 2.
Moderate-to-high risk. Notification pathway in Thailand. AMDD Class C documentation corresponds to Thai Class 3.
High risk. Full license pathway in Thailand. AMDD Class D documentation corresponds to Thai Class 4.
This equivalence applies to the ASEAN harmonization framework. FDA risk categories (Class I, II, III under 21 CFR) and EU MDR risk classifications (Class I, IIa, IIb, III) use different criteria and do not map directly to AMDD classes. A device classified as FDA Class II or EU MDR Class IIb may be Thai Class 3 or Class 4 under AMDD criteria, depending on the specific intended use and invasiveness profile. Classification by analogy to FDA or EU MDR class is a common source of misclassification in Thai submissions.
ISO 13485:2016 certification is mandatory for Class 2, 3, and 4 device submissions in Thailand. It is not required for Class 1 listing devices; Class 1 devices must follow Thai GMP guidelines instead. Thai FDA publishes ISO 13485 guidance under the MDCD.
The ISO 13485 certificate must be current at submission and remain current throughout the review period. An expired or suspended certificate stops a Class 2, 3, or 4 application from advancing. Certificate renewal timing should be tracked as part of the submission planning timeline, not managed separately from it.
ISO 13485 certification covers the manufacturer's quality management system. It does not substitute for product-specific clinical evidence, risk management documentation, or CSDT format compliance. It is one of several mandatory prerequisites for non-Class 1 submissions, not a stand-alone qualification for registration.
We classify against AMDD criteria, applied to the device's intended use in Thailand. We do not carry forward the FDA or EU MDR classification as a default. When the intended use in the Thai submission differs from the home-market registration, we work through the classification analysis from the beginning.
Classification is confirmed before the dossier is assembled. The cost of a misclassification discovered at screening is measured in months and in re-registration fees. The cost of confirming the correct class before filing is a structured analysis at the start of the engagement.